Pcn77 - Budget Impact Analysis of Blinatumomab for the Treatment of Pediatric Patients With Philadelphia Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Mexico

Abstract

paclitaxel or docetaxel, after adjuvant chemotherapy. For mBC, associations with docetaxel or paclitaxel were considered for first line and monotherapy for second. A survey was performed with 28 HMOs to map fees and sources used for reimbursement of drugs, materials and procedures. Resource use estimates were performed by a multidisciplinary team. Direct medical costs were included; drugs and material prices were obtained from published sources and fees from survey results. Time horizon was 5 years and market share considered the uptake of subcutaneous trastuzumab starting with 20% in the first year, increasing to 100% in the fifth year. A deterministic sensitivity analysis was conducted to analyze model robustness. RESULTS: In 5 years, 31,589 breast cancer patients were estimated for the private healthcare system, 284 patients for big, 30 patients for medium, and 6 patients for small HMOs. The progressive uptake of subcutaneous trastuzumab, compared with intravenous, can save up to 948,2 mBRL, 14,3 mBRL, 1,5 mBRL and 0,2 mBRL, respectively. Materials and support procedures along with medical fees were the most sensitive parameters. CONCLUSIONS: Compared with the intravenous administration, subcutaneous trastuzumab can save up to 948,2 mBRL costs on breast cancer treatment in the Private Healthcare System.